AEYE Health Autonomous Diagnostic Screening Using Retinal Images
We're building a technology platform to enable screening for a broad range of diseases — from ocular conditions to systemic diseases — using a simple, non-invasive retinal image.
Our autonomous screening detects 12 different sight-threatening indications — including glaucoma, AMD, DME, occlusions, hypertensive retinopathy, and papilledema.
Using simple retinal images, our system detects systemic diseases including diabetes, cardiovascular disease, hypertension, and dementia — enabling early intervention.
Our novel AI model predicts disease onset before diagnosable symptoms manifest — offering patients an opportunity for early intervention and potential prevention.
Diabetic Retinopathy
Diabetic retinopathy is the leading cause of blindness in American working-age adults. High blood sugar levels damage blood vessels in the retina, resulting in progressive loss of vision if left untreated. In early stages, symptoms are often unrecognized.
Long periods of high blood sugar lead to accumulation of fluid in the blood vessels, causing blockages or leaks that affect vision. The risk increases with time and poor glycemic control.
- 40M+ US adults at risk
- 95% Blindness preventable
- >60% Miss annual screening
Tabletop retinal camera for clinic-based screening with instant AI diagnosis on the AEYE-DS platform.
Portable Aurora AEYE camera enabling point-of-care screening anywhere no dilation required.
Groundbreaking Accuracy for a Broad Range of Diseases
AEYE-DS sets the highest clinical standard — the industry's only portable FDA De Novo cleared autonomous diagnostic solution.
Correctly identifies patients with diabetic retinopathy who need follow-up care.
Correctly clears patients without DR, avoiding unnecessary referrals and overdiagnosis.
Virtually every patient gets a usable image — even without dilation.
Diabetic retinopathy is the leading cause of blindness in working-age adults in the US. Our FDA-cleared technology enables accessible early detection, which can save the sight of millions.
Glaucoma is the second most common cause of blindness worldwide. Our algorithm enables early detection and accessible screening. Our results are the first to show high agreement with eye doctors.
Age-related Macular Degeneration is an extremely common condition which impairs sharp central vision. Our algorithm enables early detection, which can dramatically slow disease progression. Results for our best-in-class solution will be published imminently.
Building Toward a Broad Disease Screening Platform
What began as a focused diabetic retinopathy solution has evolved into a multi-disease AI platform. By leveraging the rich diagnostic information captured in a single retinal image, AEYE's technology roadmap extends to cardiovascular diseases, hypertension, and early neurodegenerative disease markers.
Each indication on our platform benefits from the same fundamental insight: the retina is a window into systemic health, and AI can read that window faster and more accurately than ever before.
-
FDA clearedDiabetic Retinopathy
Autonomous AI, portable, FDA De Novo cleared
-
PipelineGlaucoma
High agreement with ophthalmologists, results published
-
PipelineAMD
Best-in-class accuracy, publication imminent
-
AlphaDementia Detection
Early-stage systemic disease prediction research
-
ResearchCardiovascular
Retinal biomarkers for cardiovascular risk
-
ResearchHypertension
Hypertensive retinopathy detection algorithm
Peer-Reviewed Publications
-
ReadAutonomous AI-based diabetic retinopathy screening using single image per eye with high sensitivity and specificity
Multi-center clinical validation study demonstrating 92.5% sensitivity and 93.0% specificity across diverse patient populations without dilation.
-
ReadDeep learning-based glaucoma screening: high agreement with ophthalmologic evaluation in primary care settings
First study to demonstrate high inter-rater agreement between AI-based glaucoma screening and board-certified ophthalmologists in point-of-care workflows.
-
ReadPerformance of a portable autonomous AI for diabetic retinopathy in a real-world primary care population
Pivotal FDA De Novo study demonstrating >99% imageability rate and clinical-grade diagnostic accuracy across multi-site primary care clinics.
Turn every routine diabetic
visit into a completed eye exam
See AEYE-DS in a 30-minute demo tailored to your clinic's workflow, EHR setup, and
patient population.
FDA-cleared · No obligation · Tailored to your EHR